Stockscreener 앱 받기
20.35
1.88%
-0.39
시간 외 거래:
19.95
-0.40
-1.97%
전일 마감가:
$20.74
열려 있는:
$20.65
하루 거래량:
326.28K
Relative Volume:
1.33
시가총액:
$561.15M
수익:
$11.88M
순이익/손실:
$-162.08M
주가수익비율:
-1.6301
EPS:
-12.484
순현금흐름:
$-156.43M
1주 성능:
+10.12%
1개월 성능:
-17.94%
6개월 성능:
+34.95%
1년 성능:
+3,880%
1일 변동 폭
$19.70
$21.14
1주일 범위
$18.40
$21.24
52주 변동 폭
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
명칭
Crescent Biopharma Inc
전화
617-430-5595
주소
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
20.35 | 571.90M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Piper Sandler | Overweight |
| 2026-01-21 | 개시 | Guggenheim | Buy |
| 2025-08-25 | 개시 | Jefferies | Buy |
| 2025-08-11 | 개시 | H.C. Wainwright | Buy |
| 2025-07-14 | 개시 | Wedbush | Outperform |
| 2025-06-25 | 개시 | Stifel | Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
CBIO: Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions - TradingView
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Crescent Biopharma to present CR-001 trial data at ASCO meeting - Investing.com Nigeria
Crescent Biopharma to present CR-001 trial data at ASCO meeting By Investing.com - Investing.com South Africa
Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027 - Quiver Quantitative
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 ... - Caledonian Record
Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan
Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO) - Stock Titan
New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - 富途牛牛
Balyasny entities disclose 1.51M shares in Crescent Biopharma (CBIO) - Stock Titan
Crescent Biopharma Announces Grants of Inducement Awards - ChartMill
Crescent Biopharma gives 5 new hires options on 129,075 shares - Stock Titan
Number of shareholders of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
CBIO Crescent Bio jumps 4% as Q1 loss beats estimates by 27%, pipeline progress lifts investor confidence.Trading Community - Newser
Rainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic - simplywall.st
Crescent Biopharma lines up 3 May conference webcasts for investors - Stock Titan
Crescent Biopharma to Present at May Investor Conferences - ChartMill
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Sahm
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3%Here's Why - MarketBeat
The numbers behind Crescent Bio (CBIO) stock nobody talks about (Technical Weakness) 2026-05-03 - newser.com
MSN Money - MSN
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga
Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo
Crescent Biopharma Inc (CBIO) - MSN
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO) - The Globe and Mail
CBIO Price Today: Crescent Biopharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
12 Health Care Stocks Moving In Friday's Pre-Market SessionAkanda (NASDAQ:AKAN), Akari Therapeutics (N - Benzinga
Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27 - Moomoo
A Quick Look at Today's Ratings for Crescent Biopharma(CBIO.US), With a Forecast Between $27 to $35 - Moomoo
Crescent Biopharma: Q1 Earnings Snapshot - Barchart.com
Crescent Biopharma (CBIO) registers 19.58M ordinary shares for resale - Stock Titan
Crescent Biopharma (NASDAQ: CBIO) posts Q1 2026 loss and oncology pipeline update - Stock Titan
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma (CBIO) Q1 2026 results show $23.3M loss and $189M cash - Stock Titan
Crescent Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Crescent lines up 2027 cancer trial readouts with cash into 2028 - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Crescent Biopharma Grants Equity Inducement Awards to New Employees as Part of 2025 Incentive Plan - Quiver Quantitative
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Crescent Bio (CBIO) Stock: Is It Losing Momentum | Q4 2025: Better Than ExpectedWall Street Picks - Xã Châu Thành
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Crescent Biopharma (CBIO) - The Globe and Mail
CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed - Quiver Quantitative
Form DEFA14A CRESCENT BIOPHARMA, INC. - StreetInsider
Crescent Biopharma (NASDAQ: CBIO) outlines 2026 AGM votes on board, pay and auditor - Stock Titan
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) vs. Crescent Biopharma (NASDAQ:CBIO) Head to Head Review - Defense World
Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis
Crescent Biopharma Inc (CBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):